# Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone

> **NCT03304418** · PHASE2 · COMPLETED · sponsor: **University of Utah** · enrollment: 20 (actual)

## Conditions studied

- Prostate Cancer Metastatic to Bone

## Interventions

- **DRUG:** Radium Ra 223 Dichloride
- **RADIATION:** Radiation

## Key facts

- **NCT ID:** NCT03304418
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-27
- **Primary completion:** 2022-09-30
- **Final completion:** 2023-08-31
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03304418

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03304418, "Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03304418. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*